We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name BRAF V600E/K
Gene Variant Detail

BRAF V600E/K (gain of function)

Relevant Treatment Approaches BRAF Inhibitor MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RAF Inhibitor (Pan)

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01512251 Phase Ib/II Buparlisib + Vemurafenib BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma Completed USA 0
NCT02027961 Phase Ib/II Dabrafenib + Durvalumab + Trametinib Durvalumab + Trametinib Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone Completed USA | ITA | FRA | CAN 0
NCT01585415 Phase I Vandetanib Vemurafenib and White Blood Cell Therapy for Advanced Melanoma Terminated USA 0
NCT02427893 Phase III Cobimetinib Vemurafenib Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma Withdrawn USA 0
NCT02224781 Phase III Ipilimumab + Nivolumab Dabrafenib + Trametinib Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Active, not recruiting USA 0
NCT01682083 Phase III Dabrafenib + Trametinib Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD) Completed USA | SWE | POL | NZL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 3
NCT01978236 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites Terminated USA | AUS 0
NCT04655157 Phase Ib/II Encorafenib + Ipilimumab + Nivolumab Binimetinib + Encorafenib + Ipilimumab + Nivolumab Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01) Terminated USA 0
NCT03272464 Phase I Dabrafenib + Itacitinib + Trametinib INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. Terminated USA 0
NCT03026517 Phase I Dabrafenib + Phenformin + Trametinib Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma Completed USA 0
NCT02196181 Phase II Dabrafenib + Trametinib Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03101254 Phase Ib/II Cobimetinib + LY3022855 + Vemurafenib LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma Completed USA 0
NCT06079333 Phase II Dabrafenib + Trametinib NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) (NEO-ATACT) Recruiting NLD 0
NCT01767454 Phase I Dabrafenib + Ipilimumab + Trametinib Dabrafenib + Ipilimumab Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma Completed USA 0
NCT01657591 Phase I Vemurafenib + XL888 Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Completed USA 0
NCT02200562 Phase Ib/II Dabrafenib + Ipilimumab Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma Terminated USA 0
NCT02818023 Phase I Cobimetinib + Pembrolizumab + Vemurafenib Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma Terminated USA 0
NCT04527549 Phase II Dabrafenib + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma Terminated USA 0
NCT01909453 Phase III Vemurafenib Encorafenib Binimetinib + Encorafenib Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS) Completed USA | TUR | SWE | SVK | POL | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | AUS | ARG 8
NCT01947023 Phase I Dabrafenib + Lapatinib Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01940809 Phase II Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery Terminated USA 0
NCT01682213 Phase II Dabrafenib Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation Completed USA 0
NCT03551626 Phase III Dabrafenib + Trametinib Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus) Completed TUR | SWE | SVN | SVK | POL | NOR | LVA | LTU | ITA | ISR | HUN | GRC | GBR | FRA | FIN | CZE | CAN | BRA | AUS | ARG 3
NCT01781026 Phase II Vemurafenib Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases Completed USA 0
NCT01989585 Phase Ib/II Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma Active, not recruiting USA 0
NCT03455764 Phase Ib/II Dabrafenib + MCS110 + Trametinib MCS110 With BRAF/MEK Inhibition in Patients With Melanoma Completed USA 0
NCT02097225 Phase I Dabrafenib + Onalespib + Trametinib Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Terminated USA 0
NCT01495988 Phase II Bevacizumab Vemurafenib Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Terminated USA 0